Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing open-label study of subcutaneous anakinra in Chinese patients with CAPS
CTR20263665Phase 4Active
- Sponsor
- Sobi
- Start
- Sep 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anakinra in cryopyrin-associated periodic syndrome (CAPS), sponsored by Sobi. Primary endpoint: Complete remission at Week 4. Started Sep 2026; status: active.
02
Drugs
anakinra
03
Conditions
cryopyrin-associated periodic syndrome (CAPS)
Beyond the preview
Go deeper on CTR20263665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263665.